Want to see BBOT full AI Analyst Report?
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$7.00 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$727.98M
Enterprise Value-$222.59
Total Cash (Recent Filing)$225.71M
Total Debt (Recent Filing)$2.51M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 18, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-709.70
Shares Outstanding80,174,270
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.33Price Target Upside77.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt limits interest and refinancing pressure while BBOT funds development. This gives the company greater financial flexibility than a highly levered biotech, although it does not remove the need for future capital.
Substantial Equity BaseA substantial equity base provides a stronger capitalization foundation for clinical development and operations. Although equity has declined from 2025, the balance sheet remains materially healthier than in 2021–2023, when equity was negative.
Precision Oncology FocusA focus on genetically defined cancers can support biomarker-led development and more targeted patient selection. This strategy may improve clinical positioning and development efficiency if BBOT converts its research programs into successful therapies.
Bears Say
No Commercial RevenueBBOT has no commercial revenue stream to fund research, trials, or corporate costs. Until a product reaches the market or a partnership generates recurring income, the company remains dependent on financing and clinical execution.
Widening Net LossesThe widening loss trajectory indicates that operating and research spending is growing faster than any offsetting income. Persistent losses can erode capital, increase financing needs, and reduce the company’s ability to self-fund development.
Heavy Cash BurnDeeply negative operating and free cash flow shows that reported losses are translating into substantial cash outflows. This creates ongoing dependence on external capital and raises dilution or funding-risk concerns if development spending remains elevated.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $7.00 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $727.98M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
BridgeBio Oncology Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
BridgeBio Oncology Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of -$0.565 by -$0.14.
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate is -0.69.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,174,270 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
BridgeBio Oncology Therapeutics reported an EPS of -$0.705 in its last earnings report, missing expectations of -$0.565. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (77.39% Upside)
$22.33 (77.39% Upside)
Blogger Sentiment
Bullish
BBOT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 355.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.84%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
BBOT Stock 12 Month Forecast
Average Price Target
$22.33
▲(77.39% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Kura Oncology
―
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Ownership Overview
40.70% Insiders
3.36% Mutual Funds
7.65% Other Institutional Investors
43.89% Public Companies and
Individual Investors